Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 76842, held by Taro. Hydrocortisone Butyrate.
As of Nov 16, 2026, ANDA 76842 (Hydrocortisone Butyrate), held by Taro, was first approved by FDA on Dec 27, 2004, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Hydrocortisone Butyrate Ointment, 0.1% and Hydrocortisone Butyrate Cream USP, 0.1% are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Hydrocortisone Butyrate Topical Solution, 0.1% is
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 27, 2004 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydrocortisone Butyrate0.1% · ointment;topical | Hydrocortisone Butyrate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters